Industry landscape in nature and wildflowers Credit: LParkerPhotography
Ramboll helped a global pharmaceutical company to understand and strategically address biodiversity issues across their more than 40 sites worldwide. We assessed risks and opportunities derived from impacts and dependencies on biodiversity and ecosystems, and formulated templates for reporting in accordance with the Corporate Sustainability Reporting Directive (CSRD). This multi-phase endeavour aligned with international guidelines and sustainability goals, and examined pertinent regulations and voluntary programmes.
Leveraging this data, Ramboll developed a corporate biodiversity strategy roadmap that articulates the company’s vision for biodiversity and plots the course for measuring impact, setting targets, and implementing actions to protect and enhance biodiversity.
Understanding and addressing complex biodiversity risks
A comprehensive corporate strategy for biodiversity must encompass all aspects of a company’s complex interaction with biodiversity across its value chain. Failing to address the biodiversity impacts and dependencies of a company’s operations, or failing to incorporate the topic into existing sustainability efforts, can pose multiple risks to businesses from pressures such as increased regulatory scrutiny, heightened public awareness, and the intrinsic economic dependence on nature’s resources. At the same time, it’s crucial to stay abreast of the the latest and most innovative solutions in this new and rapidly evolving field.
With our support, the client has begun to understand the complexities of the biodiversity risks and opportunities directly linked to their operations. This allows them to prioritise areas of greatest need and potential impact, while also preparing them for the forthcoming reporting requirements of the CSRD.
As the client continues to develop and refine their strategy, the insights derived from this project will contribute to the goals of managing and mitigating biodiversity-related risks, seizing related opportunities, and promoting the long-term viability of the ecosystems the client depends on. This commitment not only benefits nature but also strengthens the company’s environmental reputation and business resilience.

Background for the biodiversity strategy roadmap

  • : 40+
    sites around the world for which biodiversity risk assessments were undertaken for the global pharmaceutical manufacturer
  • : 60+
    global and regional legislation, initiatives, and frameworks screened for relevance
  • : 8
    months of work and two workshops to complete the project

“The outcome of the project proves that we have found the right partner for this topic with Ramboll.”

Head of Global Environment & Sustainability Management
Glob­al phar­ma­ceut­ical com­pany

Let’s close the gap on biodiversity

With nature-positive solutions, we can drive economic growth while improving biodiversity.
Discover more